Tirzepatide (tesilcipapitide) declared for listing in China, is the king of falling sugar!

On September 7, 2022, the marketing application of Eli Lilly GLP-1R/GIPR dual-target agonist Tirzepatide injection was accepted by NMPA

On May 13, 2022, Tirzepatide was approved for marketing by the FDA for the treatment of type 2 diabetes under the trade name Mounjaro

Tirzepatide showed a hypoglycemic and weight-loss effect superior to that of semegglutide and the like in phase III clinical trials

Resources:

JAMA: Eli Lilly's new hypoglycemic drug tirzepatide can significantly improve diabetic blood sugar and weight levels

NEJM: Tirzepatide treats severe obesity once a week with excellent results! (SURMOUNT-1 study)

Lancet: Tirzepatide is better at controlling blood sugar in patients with T2DM than insulin without increasing the risk of cardiovascular disease!

Lancet: Type 2 diabetes treatment, Eli Lilly tirzepatide clinically beats the "net red hypoglycemic drug" somalutripe!

NEJM: Type 2 diabetes treatment, Tirzepatide is superior to somaglutide!

NEJM: Tirzepatide head-to-head phase III study was successfully studied to reduce glucose and weight loss better than somaglutide

The FDA approved the dual-targeted type 2 diabetes drug Mounjaro, which can help non-diabetic patients lose 22.

https://mp.